)
Our featured content
Unlocking Startup Potential: The Vi Partners 4Ps Blueprint
At Vi Partners, we're not just about crunching numbers; we're treasure hunters. What are we digging for? The future leaders of the B2B SaaS universe, particularly in Europe and Switzerland.
)
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing
Funding extends Xeltis’ Series D2 financing round to €44.5 million.
)
Oculis announce positive results from a Phase 3 OPTIMIZE trial showing that a daily does of OCS-01 eye drops treats inflammation and pain following cataract surgery
OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery Once daily OCS-01 meets primary endpoints demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgery OPTIMIZE’s results follow the positive and statistically significant top line results from stage 1 of the Phase 3 DIAMOND trial in Diabetic Macular Edema (DME) reported earlier this year, further highlighting the product’s potential for treating front- and back-of-the-eye diseases
)
Empowering Breast Cancer Screening Globally - Why we invested in Vara
Last year, Vi Partners led a Series A2 round in Vara (www.vara.ai), a pioneering company focused on democratising breast cancer screening and improving women's healthcare outcomes. We are thrilled to partner with Vara's exceptional team, who are driven by the ambition to transform how breast cancer screenings are conducted, ensuring accessibility, accuracy, and a patient-centric approach.
)
Building the digital healthcare enterprise ecosystem – customer by customer
Giving European Healthcare enterprises, a digital upgrade is hard. Let’s explore the challenges and some of the lights on the horizon. The prosperity and health of all of us depends on keeping our health care systems effective. To make sure this is achieved and remains affordable, we need to leverage digital transformation.
)
Oculis Announces Positive Top Line Results
Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
Why did we invest in time management application Morgen.so?
Last summer, the Vi Partners technology team led a pre-seed round in Morgen.so. We are delighted to partner with a ground breaking time management application built by a stellar team that has the ambition to transform how knowledge workers deal with their time, boost their productivity while improving their worklife balance and overall wellbeing.
)
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices
Xeltis, a clinical stage medtech company developing living implants that enable the body to restore cardiovascular function, announces that it has raised €32 million in a Series D2 equity fundraise.
){kind=logo}
Switzerland-Based Acodis Closes CHF 6 million Series A Funding Round to Transform Document Processing for Pharma and Health
The Swiss AI start-up Acodis closed a CHF 6m financing round from existing and new investors. Acodis, the leading Intelligent Document Processing (IDP) platform, raised CHF 6 million in a Series A funding round led by Hi Inov and VI Partners. The new funds will be used to further expand Acodis' position as the leading Document Processing Platform for the Pharma and Health sector.
)
Latest News
)
)
)
)
Entrepreneurs improve the world. We proudly support them.
Our heritage
Who we are and how we started
Vi Partners' founding team came together in 2000 to advise Venture Incubator, an investment vehicle initiated by ETHZ and funded by ten blue-chip Swiss companies. Today, we advise funds investing across Europe in tech and healthcare.
)